10-23-2009: Kinaxo Biotechnologies GmbH announced that it has entered into a collaboration with Roche Diagnostics GmbH. Under the agreement KINAXO's phosphoproteomics technology PhosphoScout® will be applied to support the identification of biomarkers related to new treatment approaches based on therapeutic antibodies currently under development at Roche. Financial details of the agreement were not disclosed.

Dr. Klaus Godl, KINAXO’s CSO commented: “We are very pleased to partner with Roche, a world leading healthcare company. Cellular signal transmission in eukaryotic cells is mainly regulated by the reversible phosphorylation of proteins. Therefore, differential analysis of the complete cellular phosphoproteome upon drug treatment provides highly informative insights into the modes of action of targeted cancer drugs.”

Contact / Request information

Request further information free of charge:

Facts, background information, dossiers
More about Roche Diagnostics
More about Roche
More about Kinaxo Biotechnologies
Most read news
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE